Preliminary Findings from the National Register of Antipsychotic Medication in Pregnancy

Kulkarni, Jayashri; McCauley-Elsom, Kay Madelon; Marston, Natasha; Gilbert, Heather; Gurvich, Caroline; Castella, Anthony de; Fitzgerald, Paul B.

doi:10.1080/00048670701732723

Cited by 43 publications

(49 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It seems prudent to suggest that pregnant women treated with olanzapine should be offered an oral glucose tolerance test, particularly if they have a raised BMI: indeed, in light of recent research finding an increased risk of gestational diabetes in women prescribed antipsychotics in pregnancy [Boden et al 2012], we would suggest all women prescribed antipsychotics with raised prepregnancy/first trimester BMI should be offered this test. In addition, it would be potentially helpful to consider the creation of an international register to monitor routinely the maternal and foetal outcomes of antipsychotic use in pregnancy [Kulkarni et al 2008].…”

Section: Resultsmentioning

confidence: 99%

Neonatal hypoglycaemia following maternal olanzapine therapy during pregnancy: a case report

Rowe

Gowda

Taylor

et al. 2012

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Neonatal hypoglycaemia following maternal olanzapine therapy during pregnancy: a case report

Rowe

Gowda

Taylor

et al. 2012

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

“…Gonadal steroid hormones act in the CNS to affect the drug response and are different in men and women (Kulkarni et al, 2008b). Tardive dyskinesia is seen more commonly in women than men (Usall et al, 2007;Yassa and Jeste, 1992).…”

Section: Development Of Schizophrenia In Womenmentioning

confidence: 99%

“…An evidence-based guideline for antipsychotic prescribing during pregnancy is needed. The Australian National Register of Antipsychotic Medication in Pregnancy (NRAMP) will provide local data towards developing such guidance (Kulkarni et al, 2008b(Kulkarni et al, , 2014b). An NRAMP prospective cohort study (Kulkarni et al, 2014b) found that cessation of antipsychotic medication during pregnancy was associated with relapse of psychosis, maternal hospitalisation and the subsequent separation of mother and baby, leading to attachment and bonding problems.…”

Section: Development Of Schizophrenia In Womenmentioning

confidence: 99%

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders

Galletly

Castle

Dark

et al. 2016

Aust N Z J Psychiatry

Self Cite

643

672

View full text Add to dashboard Cite

Objectives: This guideline provides recommendations for the clinical management of schizophrenia and related disorders for health professionals working in Australia and New Zealand. It aims to encourage all clinicians to adopt best practice principles. The recommendations represent the consensus of a group of Australian and New Zealand experts in the management of schizophrenia and related disorders. This guideline includes the management of ultra-high risk syndromes, first-episode psychoses and prolonged psychoses, including psychoses associated with substance use. It takes a holistic approach, addressing all aspects of the care of people with schizophrenia and related disorders, not only correct diagnosis and symptom relief but also optimal recovery of social function. Methods:The writing group planned the scope and individual members drafted sections according to their area of interest and expertise, with reference to existing systematic reviews and informal literature reviews undertaken for this guideline. In addition, experts in specific areas contributed to the relevant sections. All members of the writing group reviewed the entire document. The writing group also considered relevant international clinical practice guidelines. Evidence-based recommendations were formulated when the writing group judged that there was sufficient evidence on a topic. Where evidence was weak or lacking, consensus-based recommendations were formulated. Consensus-based recommendations are based on the consensus of a group of experts in the field and are informed by their agreement as a group, according to their collective clinical and research knowledge and experience. Key considerations were selected and reviewed by the writing group. To encourage wide community participation, the Royal Australian and New Zealand College of Psychiatrists invited review by its committees and members, an expert advisory committee and key stakeholders including professional bodies and special interest groups. RANZCP GuidelinesGalletly et al. 411 Australian & New Zealand Journal of Psychiatry, 50(5)Results: The clinical practice guideline for the management of schizophrenia and related disorders reflects an increasing emphasis on early intervention, physical health, psychosocial treatments, cultural considerations and improving vocational outcomes. The guideline uses a clinical staging model as a framework for recommendations regarding assessment, treatment and ongoing care. This guideline also refers its readers to selected published guidelines or statements directly relevant to Australian and New Zealand practice. Conclusions:This clinical practice guideline for the management of schizophrenia and related disorders aims to improve care for people with these disorders living in Australia and New Zealand. It advocates a respectful, collaborative approach; optimal evidence-based treatment; and consideration of the specific needs of those in adverse circumstances or facing additional challenges.

show abstract

“…2005, the National Register of Antipsychotic Medication in Pregnancy (NRAMP) was established as an ongoing prospective observational cohort study, enrolling women from Australia and New Zealand (17,22).…”

mentioning

confidence: 99%

Reproductive Safety of Second-Generation Antipsychotics: Current Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics

Cohen¹,

Viguera²,

McInerney³

et al. 2016

AJP

168

View full text Add to dashboard Cite

The results suggest that it would be unlikely for second-generation antipsychotics to raise the risk of major malformations more than 10-fold beyond that observed in the general population or among control groups using other psychotropic medications. If the estimate stabilizes around the null with ongoing data collection, findings may be reassuring for both clinicians and women trying to make risk-benefit treatment decisions about using atypical antipsychotics during pregnancy. These findings are timely given the renewed focus of regulatory agencies on reproductive safety.

show abstract

Preliminary Findings from the National Register of Antipsychotic Medication in Pregnancy

Cited by 43 publications

References 27 publications

Neonatal hypoglycaemia following maternal olanzapine therapy during pregnancy: a case report

Neonatal hypoglycaemia following maternal olanzapine therapy during pregnancy: a case report

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders

Reproductive Safety of Second-Generation Antipsychotics: Current Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics

Contact Info

Product

Resources

About